A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Trial Profile

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms Harmony AD; Harmony-AD; HarmonyAD
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 10 Nov 2015 According to a Transition Therapeutics media release, data from this trial was presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting.
    • 28 Oct 2015 Data from this trial will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) 2015, according to a Transition Therapeutics media release.
    • 15 Oct 2015 Data of this trial will also be presented at the Clinical Trials in Alzheimer's Disease meeting in Barcelona, as per Transition Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top